In this report, we define the level of the EV markers; CD9, CD63, CD81, CD147 as well as CD38, CD55, CD59 and PD-L1 on PB EVs and BM EVs from MM patients treated with DARA and healthy control PB EVs. This evidence concerns the gene CD38 and Miyoshi myopathy.